Article
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2011
Hof Jana, Krentz Stefanie, van Schewick Claudia, Körner Gabriele, Shalapour Shabnam, Rhein Peter, Karawajew Leonid, Ludwig Wolf-Dieter, Seeger Karl, Henze Günter, von Stackelberg Arend, Hagemeier Christian, Eckert Cornelia, Kirschner-Schwabe Renate
Abstract excerpt
PURPOSE: In the clinical management of children with relapsed acute lymphoblastic leukemia (ALL), treatment resistance remains a major challenge. Alterations of the TP53 gene are frequently associated with resistance to chemotherapy, but their significance in relapsed childhood ALL has remained controversial because of small studies. PATIENTS AND METHODS: Therefore, we systematically studied 265 first-relapse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.